Patents by Inventor Ivor Royston
Ivor Royston has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100330030Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: May 14, 2010Publication date: December 30, 2010Applicant: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Publication number: 20100278811Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: December 1, 2009Publication date: November 4, 2010Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Publication number: 20070208019Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: January 11, 2007Publication date: September 6, 2007Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Patent number: 7208493Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: GrantFiled: October 2, 2003Date of Patent: April 24, 2007Assignee: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Publication number: 20050282814Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: April 13, 2005Publication date: December 22, 2005Applicant: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Publication number: 20040167198Abstract: Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases , inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.Type: ApplicationFiled: October 2, 2003Publication date: August 26, 2004Applicant: TargeGen, Inc.Inventors: Wolfgang Wrasidlo, John Doukas, Ivor Royston, Glenn Noronha, John D. Hood, Elena Dneprovskaia, Xianchang Gong, Ute Splittgerber, Ningning Zhao
-
Patent number: 5681562Abstract: A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to tumor antigens. In one embodiment, autologous fibroblasts genetically modified to secrete at least one cytokine gene product are utilized to immunize the patient in a formulation with tumor antigens at a site other than an active tumor site. In another embodiment, cells genetically modified to express at least one tumor antigen gene product and to secrete at least one cytokine gene product are utilized in a formulation to immunize the patient at a site other than an active tumor site.Type: GrantFiled: December 9, 1994Date of Patent: October 28, 1997Assignee: Sidney Kimmel Cancer CenterInventors: Robert E. Sobol, Fred H. Gage, Ivor Royston, Theodore Friedman, Habib Fakhrai
-
Patent number: 5674486Abstract: A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to tumor antigens. In one embodiment, autologous fibroblasts genetically modified to secrete at least one cytokine gene product are utilized to immunize the patient in a formulation with tumor antigens at a site other than an active tumor site. In another embodiment, cells genetically modified to express at least one tumor antigen gene product and to secrete at least one cytokine gene product are utilized in a formulation to immunize the patient at a site other than an active tumor site.Type: GrantFiled: June 6, 1995Date of Patent: October 7, 1997Assignee: San Diego Regional Cancer CenterInventors: Robert E. Sobol, Fred H. Gage, Ivor Royston, Theodore Friedmann
-
Patent number: 4675386Abstract: Methods and compositions are provided for producing monoclonal antibodies capable of distinguishing between antigenic aggregates, which are differentiated by one or a small number of antigenic determinants. The method involves immunization of a mammal to produce spleen cells which are fused with a cell line which is stable in vitro. The hybridized cells are then dispensed into culture wells at a density level which encourages the production of one colony per well. Autologous antigenic aggregates are employed for screening to distinguish the antibodies which discriminate between the antigenic aggregates. Particularly, mice are hyperimmunized with a homogeneous population of T-cells, the immunized mice killed and the spleens removed. The spleen cells are fused with mouse myeloma cells and the resulting hybrids plated at a relatively low density in culture wells. Plates containing fewer than 30% hybrid positive wells are found to have primarily one colony per well.Type: GrantFiled: May 19, 1983Date of Patent: June 23, 1987Assignee: Regents of the University of CaliforniaInventors: Ivor Royston, John Majda, Gayle Yamamoto
-
Patent number: 4451570Abstract: Novel human lymphoblastoid cells and hybridomas derived therefrom are provided. The cells are a HGPRT negative human B-cell line. The cells are readily fusible with lymphoid cells to produce hybridomas which secrete human monoclonal antibodies.Type: GrantFiled: March 26, 1981Date of Patent: May 29, 1984Assignee: The Regents of the University of CaliforniaInventors: Ivor Royston, Harold Handley, J. Edwin Seegmiller, Linda F. Thompson